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Abstract 
The diagnosis and management of hypertension relies on accurate and precise blood pressure (BP) measurements and monitoring 
techniques. Variability in traditional office based BP readings can contribute to misclassification and potential misdiagnosis of 
hypertension, leading to inappropriate treatment and possibly avoidable adverse drug events. Both home blood pressure monitoring 
(HBPM) and 24-hour ambulatory blood pressure monitoring (ABPM) can improve characterization of BP status over traditional office 
values and can predict cardiovascular morbidity and mortality risk; however, they are limited by availability and/or practical use in 
many situations. Available in-office blood pressure measuring methods include manual auscultation, automated oscillometric, and 
automated office blood pressure (AOBP) devices. A strong correlation exists between AOBP and awake ABPM measurements and has 
been linked to better prediction of end-organ damage and white coat response compared to standard office BP methods. While AOBP 
does not provide nocturnal BP readings, it can be utilized in several outpatient settings, and has the capability to decrease utilization 
of ABPM, white coat effect, and improve optimization of cardiovascular assessment, evaluation, and therapeutic assessment in clinical 
practice. 
 
Hypertension affects over 80 million adults in the United States (US) and is a major risk factor for cardiovascular morbidity and 
mortality [1]. The condition’s ubiquitous nature and broad impact potentially makes understanding the diagnosis and treatment of 
hypertension key elements of managing cardiovascular risk.  Though much attention is paid to the treatment of hypertension, from 
2009 to 2012, 45.9% of US patients with hypertension were uncontrolled [1]. Appreciating the aspects of proper assessment of blood 
pressure is crucial and creates the foundation for approaching hypertension management. Until recently, hypertension was defined 
as an appropriately measured office systolic blood pressure (SBP) of greater than or equal to 140 mmHg and/or diastolic blood 
pressure (DBP) greater than or equal to 90 mmHg, with the patient seated and resting for 5 minutes in a proper position, and 
preferentially, measured as an average of two readings taken 1 or 2 minutes apart [1-5]. While serving as the primary method, 
standard office blood pressure assessment with either manual or traditional automated BP cuffs is limited in accuracy and 
application in everyday practice, and faces many challenges. As such, an understanding of the potential limitations of current BP 
strategies, and the roles and rationale for novel assessment techniques are of value to clinicians [6].  
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Office Blood Pressure Measurements 
Inaccuracy and variability in single office-measured BPs can 
contribute to misclassification and/or potential misdiagnosis of 
hypertension [7]. The features contributing to inconsistencies 
in office measurements can be driven by several factors, such 
as variation from proper BP measurement technique (outlined 
in Table 1), measurement of a single BP reading, and digit 
preference (rounding BP reading to 0 or 5 mmHg), all of which 
may cause deviations in BP readings and reduce accuracy [8]. 
As an example of the potentially significant impact of the timing 
of BP measurement, an evaluation showed that rechecking BP 
in the clinic a second time exhibited an average reduction of 
11/5.2 mmHg in BP compared to the initial assessment [9].  
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This follow-up BP assessment consequentially lead to a 
reclassification of BP status (SBP greater than 140 mmHg or 
DBP greater than 90 mmHg, reclassified as SBP less than 140 
mmHg or DBP less than 90 mmHg) in 49% of patients. Note, 
both readings were obtained during the same office 
appointment, and the average time between the first and 
second measurements was not specified.   
 
Observer differences may exist and impact BP assessment. A 
systematic review and meta-analysis of 15 studies found that 
physicians record BPs, on average, 7/3.8 mmHg higher than 
nurses [10].  The presence of observer variability can create 
what is known as the “white coat effect” or “white coat 
hypertension,” both of which have been defined in previous 
literature [7, 11, 12]. This white coat response affects nearly 
25% of patients with hypertension and may lead to 
misclassification of BP status, inappropriate initiation, and/or 
intensification of anti-hypertensive treatment, adverse drug 
events, and increases in healthcare costs. 
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Alternative Methods of Blood Pressure Assessment 
Because of the limitations of traditional office blood pressure 
assessment, interest has grown in the use of alternative 
strategies to measure BP, most notably focusing on home 
blood pressure monitoring (HBPM) and 24-hour ambulatory 
blood pressure monitoring (ABPM).  HBPM, with an automated 
oscillometric device, is recommended for use by several 
hypertension guidelines, as it provides a relatively inexpensive 
and convenient method for monitoring BP over long periods of 
time [13-16]. While HBPM increases the number of evaluable 
BPs and is minimally intrusive for the patient, it can require a 
significant amount of time to accrue these values. Also, its 
accuracy is predicated on the patient’s ability to use proper BP 
technique and values may be subject to reporting bias (e.g. 
reporting lower BP readings especially in patients with a 
negative medication experience) [16].  HBPM only provides an 
assessment of awake BPs, which may limit understanding of 
the patient’s entire BP phenotype.   
 
As a method to fully understand awake and asleep BP values 
and mitigate the effects of the “white coat” phenomena, ABPM 
has been considered the gold standard for diagnosing 
hypertension and providing a clinically meaningful assessment 
of BP and impact on cardiovascular risk. ABPM has also been 
endorsed by many major practice organizations [13, 14, 16-19].  
The 2011 United Kingdom guidelines on adult hypertension 
diagnosis and management recommend that ABPM be offered 
for patients with office BP greater than 140/90 mmHg [20]. 
Unfortunately, ABPM monitoring can be burdensome for 
patients and availability is limited across health care systems 
[16].  A final strategy, automated office blood pressure (AOBP) 
monitoring, provides an alternative option worthy of 
consideration by clinicians as it can mitigate or reduce the 
impact from the white coat effect and is strongly associated 
with predicting BP related end-organ damage [21, 22].  
 
Automated Office Blood Pressure Monitoring 
AOBP is a unique fully automated device which uses an 
electronic sphygmomanometer to record multiple BP readings 
in 1-2 minute intervals over 5-10 minutes, and averages the 
values while the patient rests alone in a quiet area, without 
observation by healthcare staff [23]. There are currently three 
AOBP devices (BpTRU, Omron HEM-907, and Microlife 
WatchBP Office) which have been independently validated for 
use, with slightly differing characteristics (Table 3).  This 
monitoring strategy was initially employed only in 
hypertension research, but has now been fully validated for use 
in a variety of settings.  
 
Importantly, AOBP monitoring does not appear to be affected 
by location [22, 23] and has been studied in a variety of 
different practice settings, ranging from community-based 
pharmacies [24], primary care practice exam rooms [25], 24-
hour ABPM units [8], and waiting rooms [26]. The ability to 
obtain valid AOBP readings in waiting rooms exemplifies that 
additional space or a private room is unnecessary to realize 
benefits from this device.   
 
More than 10,000 AOBP monitors are currently in use, of 
which, approximately 25% are located in primary care physician 
practices in Canada [24]. The accuracy of AOBP utility in a real-
world setting was demonstrated in The Conventional versus 
Automated Measurement of Blood Pressure in the Office 
(CAMBO) trial, which compared manual office blood pressure 
(MOBP) and AOPB versus awake ABPM in primary care practice 
settings.  Pre-enrollment mean BP of 150/81 mmHg was 
reduced to 136/78 mmHg with AOBP and 141/80 mmHg with 
MOBP compared to the awake ABPM reading of 133/74 mmHg 
[27].  In comparison with MOBP in this evaluation and others, 
a significantly stronger BP correlation exists between mean 
AOBP and awake ABPM measurements [8, 25, 27].  
 
The aforementioned correlation between AOBP and awake 
ABPM measurements extends to predicting end-organ 
damage, which may occur from sustained uncontrolled 
hypertension [28, 29]. Left ventricular mass index (LVMI) is an 
example of a surrogate for predicting intermediate-organ 
damage in hypertensive patients. When the correlations 
between LVMI and AOBP, MOBP, and awake ABPM devices 
were examined, AOBP readings were more closely associated 
with LVMI (r=0.37) than MOBP (r=0.12). The mean AOBP was 
similar to the mean awake systolic ABPM correlation to LVMI 
([r=0.34; P=0.001] and [r=0.37; P<0.001], respectively) [28]. 
AOBP, unlike MOBP, also had a significant correlation with 
carotid artery wall thickness, another predictor of end-organ 
damage [29].  
 
The definition of hypertension with AOBP (greater than or 
equal to SBP of 135 mmHg and/or greater than or equal to DBP 
of 85 mmHg) is quite similar to the defined blood pressure 
thresholds set for HBPM and mean awake ABPM [13]. AOBP 
(BpTRU device) was used to assess BP thresholds in 
determining cardiovascular risk (non-fatal and fatal events) in 
3,627 community-dwelling individuals aged greater than or 
equal to 65 years for 4.9 years as part of The Cardiovascular 
Health Awareness Program (CHAP) trial [30]. Cardiovascular 
risk was significantly elevated at SBP 135-144 mmHg (HR, 1.66; 
95% CI, 1.09-2.54 (P=0.02)) and DBP 80-89 mmHg (HR, 1.72; 
95% CI, 1.21-2.45 (P=0.003)). The results confirmed that SBP of 
less than 135 mmHg and DBP of less than 85 mmHg is a 
reasonable hypertension target to achieve with this device to 
potentially reduce the risk of cardiovascular events. 
 
Similarly to ABPM, AOBP nearly eliminates white coat response 
in patients [12]. A study examined routine MOBP versus AOBP 
(BpTRU device) in relation to mean awake ABPM in family 
physician offices; this study demonstrated a higher correlation 
between SBP/DBP mean awake ABPM and AOBP (r=0.62/0.72; 
P<0.001) compared to MOBP (r=0.32/0.48), both of which were 
measured by family physicians, with regards to white coat 
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response [8]. The outcomes were positive in both treated and 
untreated patients [8]. Given this information, AOBP has the 
potential to be an alternative to 24-hour ABPM for diagnosing 
white coat response and/or mitigating white coat effect during 
screening. However, AOBP does not provide data on nocturnal 
values, and thus poses a limitation for patients that may have 
nocturnal hypertension.  
 
Implementation in Clinical Practice and Potential Limitations 
AOBP monitoring has been recognized as an option for 
monitoring blood pressure in the Canadian Hypertension 
Education Program Guidelines [22]. Utilizing standardized and 
validated electronic oscillometric devices is recommended over 
auscultation (Grade C), but the preferred method of 
performing in-office BP measurements is by AOBP (Grade D). 
Additionally, the 2013 European Society of Hypertension and 
European Society of Cardiology states AOBP is a potential 
method to improve BP reproducibility and reconcile variations 
between office and out-of-office methods, such as awake 
ABPM and HBPM monitoring [13].  The U.S. Preventive Services 
Task Force also states that AOBP can produce similar results as 
awake ABPM, but does not make specific recommendations on 
in-office BP methods [17]. See Table 2 for in-office methods 
preferred by various guidelines.  
 
In order to successfully integrate AOBP into practice, the device 
must be fully automated and configured to record multiple 
readings. Even when AOBP was replaced with an automated 
HBPM and activated by the patient, unattended in the clinic 
setting, mean BP values were 5 mmHg higher than that of AOBP 
measurements [31]. However, white coat response still occurs 
with the initial AOBP reading; yet, BP appears to drop by 15 
mmHg within 2 minutes of the observer leaving the patient 
alone [32]. Thus, in addition to the full automation of AOBP, the 
patient must not be directly observed by healthcare staff.   
 
While there is a valuable role for AOPB in clinical practice, 
certain limitations exist as well. A critical shortcoming of AOBP 
is the inability to provide nocturnal blood pressure readings, 
which is the most significant predictor of cardiovascular 
morbidity and mortality [33]. Thus, 24-hour ABPM continues to 
be the best device available to evaluate BP control, especially 
where nocturnal hypertension may be suspected.  Additionally, 
as with most oscillometric automatic blood pressure devices, 
AOBP may be less accurate in the presence of arrhythmias such 
as atrial fibrillation [24].  
 
 AOBP has been incorporated in research for several years 
perhaps most notably in the Systolic Blood Pressure 
Intervention Trial (SPRINT) study, although the technique was 
not formally validated [34].  In this study of patients with or at 
risk for cardiovascular disease but without diabetes or 
cerebrovascular disease, pharmacologic lowering of SBP to less 
than 120 mmHg versus a traditional target of less than 140 
mmHg on AOBP measures led to a significant reduction in risk 
of a composite endpoint of cardiovascular events and death as 
well as overall mortality. Adoption of AOBP technology in 
clinical practice may facilitate the translation of the SPRINT 
findings to routine hypertension management.  
 
Pharmacists and Blood Pressure Technology 
Expansion of AOBP technology into community pharmacies, 
which are generally easily accessible to patients, may offer 
several advantages. As previously mentioned, the CHAP trial 
demonstrates a successful example of incorporation of AOBP 
screenings (along with other interventions) in community-
based pharmacies leading to improved blood pressure related 
risk assessment amongst older adults in Ontario, Canada [30]. 
AOBP devices are fairly small and easy to use; thus, increased 
availability in community pharmacies may provide an 
opportunity for patients with suspected white coat syndrome 
to validate their blood pressure status and potentially prevent 
initiation or addition of anti-hypertensive therapy and, 
conversely, those with values above the cut offs defined in the 
CHAP trial may benefit from interventions targeted at lowering 
blood pressure.  
 
Pharmacists’ involvement in the screening and management of 
hypertension has been demonstrated to improve clinical and 
economic outcomes in multiple ambulatory settings [35-38]. 
Pharmacists are often involved in directly measuring patients’ 
blood pressures using standard, calibrated devices prior               
to making pharmacotherapeutic recommendations or 
interventions [39]. As cardiovascular team-based care 
continues to expand and integrate clinical pharmacy services 
[40, 41], pharmacists could directly encounter increasingly 
changing dynamics in blood pressure monitoring, including the 
possible utilization of AOBP technology in routine medical care. 
Innovations in blood pressure monitoring techniques and 
integration of new strategies and technology are pivotal 
aspects of hypertension assessment in an evolving clinical 
practice.  
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Table 1: Technique for manual office blood pressure measurement [6] 
 
Important Instructions for Proper Manual Clinical Blood Pressure Measurement 
 
• Patient is comfortably seated, legs uncrossed, with back supported, for at least 5 minutes 
• Upper arm is free of constrictive clothing and supported at heart level 
• Blood pressure cuff is appropriately sized with at least 80% of the bladder encircling the arm circumference 
• Cuff should be deflated at 2 to 3 mm/s (first and last audible sounds taken as systolic and diastolic pressure 
read to the nearest 2 mmHg) 
• Neither the patient nor the observer should be in conversation during the blood pressure measuring 
procedure 
• At least 2 measurements should be made 
 
 
 
 
 
Table 2: Preferred In-office BP Methods per selected guidelines 
 
Guideline Preferred In-office BP Method 
The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure [42] 
Auscultation method 
Clinical Practice Guidelines for the Management of 
Hypertension in the Community: A Statement by the 
American Society of Hypertension and the International 
Society of Hypertension [2] 
Automated electronic device 
2013 European Society of Hypertension and the European 
Society of Cardiology Guidelines for the management of 
arterial hypertension [13] 
Auscultation or oscillometric semiautomatic 
sphygmomanometers 
 
Consider automated recording of multiple BP readings 
National Institute for Health and Care Excellence: 
Hypertension in adults: diagnosis and management [43] 
Automated device or manual auscultation (if pulse 
irregularity is present, then use direct auscultation) 
Hypertension Canada’s 2016 Canadian Hypertension 
Education Program Guidelines for the Blood Pressure 
Measurement, Diagnosis, Assessment of Risk, Prevention, 
and Treatment of Hypertension [22] 
Automated Office Blood Pressure measurements (Grade D) 
Screening for High Blood Pressure in Adults: U.S. 
Preventive Services Task Force Recommendation 
Statement [17] 
No particular office blood pressure measurement protocol 
recommended 
 
Manual (auscultation) or automated office BP may be used 
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Table 3: Validated Automatic Blood Pressure Devices 
 
Device (adult) BpTRU [44] Omron 907 [45] Microlife WatchBP Office [46] 
 
Mode Automated oscillometric  Automated oscillometric  Automated oscillometric 
Instruction Up to six consecutive BP 
readings are taken. The first 
reading is discarded and the 
next five are averaged. The 
average is displayed as the 
final result. 
Two to three consecutive 
BP readings are taken. The 
readings are averaged and 
displayed as the final result. 
Three inter-arm BP 
measurements are taken and 
averaged for the initial 
screening. Three single arm 
measurements are taken and 
averaged for follow-up 
screenings.  
Cost ~ $960 ~ $600 ~ $650 
 
 
 
 
 
 
 
 
 
